IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume – Time to Buy?

IPSEN (OTCMKTS:IPSEY) shares saw strong trading volume on Monday . 1,039 shares traded hands during mid-day trading, an increase of 104% from the previous session’s volume of 510 shares.The stock last traded at $37.57 and had previously closed at $36.80.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. BNP Paribas lowered shares of IPSEN to an “underperform” rating in a report on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

IPSEN Price Performance

The company has a 50 day moving average price of $36.10 and a 200-day moving average price of $34.07.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).